Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in the Baltic Region, including Lithuania, Latvia, and Estonia.

Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments, along with T2Bacteria®, T2Candida® and T2Resistance® Panels through the distributor.

The execution of this exclusive distribution agreement further expands T2 Biosystems’ commercialization. Epidemiology studies have shown that the Baltic region has a higher average incidence of sepsis per population than Western Europe.1 There have been national guidelines in the region to address the impact of sepsis.2 The introduction of the T2Dx Instrument and sepsis panels into these countries will allow rapid detection of sepsis-causing pathogens and antibiotic resistance genes, in hours instead of days, enabling clinicians to achieve targeted therapy, faster.

“We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Lithuania, Latvia, and Estonia,” said John Sperzel, Chairman and CEO of T2 Biosystems. “We believe these three countries represent additional growth potential for our culture-independent rapid diagnostics and look forward to building lasting relationships with our newly-appointed distributor as we work to improve the quality of care for patients at risk of sepsis.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine